Choom Holdings Inc., an adult use cannabis company, is currently developing one of the largest cannabis retail networks across Canada. Choom is focused on delivering an elevated customer experience through its curated retail environments, offering a diversity of brands for Canadians across a national retail network.

The Company’s primary business currently consists of the development of its bank of proprietary outdoor genetics, growing, harvesting and processing of cannabis biomass and the sale of cannabis oil, distillate and isolate.   The Company has a Standard Cultivation License and corresponding processing/sales amendment from Health Canada, a Research and Development License from Health Canada, and is also positioned to provide consulting services to Health Canada applicants and businesses licensed by Health Canada, including outdoor cultivation and extraction companies. As a means to this end, the Company has developed a significant land position for its own outdoor cultivation, the development of genetic material, testing and third-party cultivation.

CloudMD Software & Services Inc. is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. The Company is focused on innovative health care approaches that combine human skill-based expertise with emerging technologies. In conjunction with its subsidiary Cloud Practice, which offers SAAS based health technology solutions including a cloud based Electronic Medical Records (EMR) software, medical billing software and an online patient portal, the Company is developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics, telemedicine, and artificial intelligence (AI).

CloudMD Software & Services Inc. - Common Shares

Cognetivity Neurosciences Ltd. is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.